This trial is evaluating whether Talazoparib will improve 2 primary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 30 days after last dose of study treatment (+/- 3 days).
This trial requires 55 total participants across 1 different treatment group
This trial involves a single treatment. Talazoparib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"Most Pca have been treated with radical prostatectomy, but hormonal therapy has replaced this as the first-line option. Androgen-deprivation therapy has been used to treat patients with advanced disease. And adjuvant therapies are being investigated." - Anonymous Online Contributor
"Prostate cancer curative treatments are available. The potential for curative treatments to impact on the long-term survival is a challenging issue facing modern [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) management. However, further studies examining the role of early prostate-specific antigen in the detection of curative cancer are required." - Anonymous Online Contributor
"About 60,000 new cases of prostate cancer are diagnosed annually in the United States. This represents 31.9% of all new cases of prostate cancer. This is one of the highest rates of prostate cancer in the world." - Anonymous Online Contributor
"The major risk factors for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) are age, ethnicity and family history. The strongest single risk factor for prostate cancer is familial cancer in a close family relative. The risk of prostate cancer increases with degree of relatedness. The risk is also related to the age of the patient, which is lower in the relatives with less than 50% relatedness. Prostate cancer risk also is lower in the spouses of patients with prostate cancer. There is no increased risk for spouses of persons with prostate cancer from any other familial cancer, nor is there any increased risk when a spouse has breast, ovarian or gastric cancer or a male relative has cancer of the female genital tract." - Anonymous Online Contributor
"Prostate disease may develop gradually or suddenly, and may be detected as a result of a routine physical examination. Most [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer)s are not evident on physical examination, and if they are they are typically non-specific. However, if found during the physical examination other signs may indicate the possibility of prostate cancer." - Anonymous Online Contributor
"Contrary to popular belief, prostate cancer affects a significantly greater percentage of men than women. In 2007, prostate cancer affected 233,000 men in the United States, of which only 4,050 were diagnosed with a more serious prostate cancer." - Anonymous Online Contributor
"Although the genetic etiology of prostate cancer remains largely unknown, the present observational study highlights the contribution of genetic factors to familial prostate cancer. We also confirmed that familial prostate cancer, the majority of which occurs in relatives of patients with aggressive prostate cancer, should be considered a "rule" of thumb." - Anonymous Online Contributor
"Although only a small subset of patients in clinical trials had baseline scores of sufficient quality, the results from this first phase II trial with talazoparib demonstrated that in this patient population, talazoparib significantly improved quality of life. Talazoparib was associated with a marked improvement in patient-reported physical and social functioning, although its activity is currently limited by a short half-life, although long term toxicities have yet to be reported, therefore long term efficacy remains to be determined." - Anonymous Online Contributor
"Almost half of men with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) had a Gleason score of 8 or higher, which corresponds to a 5-year survival rate after diagnosis of 20% with a 10-year survival rate at 3.2%. Although prostate cancer has a low survival rate after diagnosis, the long-term risks of prostate cancer are low compared with other cancers." - Anonymous Online Contributor
"Older men with LUTS and high likelihood of disease at presentation would benefit the most from a prostate-specific antigen screening program. These cohorts should be counseled, counseled, and referred to the Mayo Clinic for further evaluation. Physicians should consider offering them a clinical trial to determine whether prostate cancer is actually under control with a standard treatment regimen. For those men, the benefits of such a trial are not only in relieving the LUTS of the bladder but by giving the patients access to the best data available from the current literature regarding the specific, best-standard prostate cancer regimen that would provide longest life expectancy and minimize side-effects." - Anonymous Online Contributor
"The risk of disease is not an independent variable. Risk of all [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer)s was 1.9% on the basis of the best available study reports (Grundy, 1998; Leloup, 1999). Risk of any form of prostate cancer is not constant. The relative risk of aggressive cancer is higher in populations of higher rates of prostate-specific antigen-detect prostate cancer. The relative risk of low-grade cancer, in populations with lower rates of detection, is greater. The probability of developing any prostate cancer in a family member may increase if both parents were men, but increased awareness and screening may also account for the higher incidence of prostate cancer seen in families." - Anonymous Online Contributor
"Patients with progressive metastatic castration-refractory prostate cancer typically receive combination therapy with androgen axis targeting chemotherapy and/or the synthetic retinoid analog talazoparib in addition to androgen deprivation. The clinical experience gathered during multiple phase III trials of the above agents as second-line, salvage, and/or third-line chemotherapy for patients with castration resistant prostate cancer has led to a more accurate appreciation of their respective roles as therapy, and more nuanced application of these agents in the clinical setting." - Anonymous Online Contributor